Tags

Type your tag names separated by a space and hit enter

Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany.
Value Health. 2021 01; 24(1):32-40.VH

Abstract

OBJECTIVES

In Germany, routine influenza vaccination with quadrivalent influenza vaccines (QIV) is recommended and reimbursed for individuals ≥60 years of age and individuals with underlying chronic conditions. The present study examines the cost-effectiveness of a possible extension of the recommendation to include strategies of childhood vaccination against seasonal influenza using QIV.

METHODS

A dynamic transmission model was used to examine the epidemiological impact of different childhood vaccination strategies. The outputs were used in a health economic decision tree to calculate the costs per quality-adjusted life year (QALY) gained from a societal and a third-party payer (TPP) perspective. Strain-specific epidemiology, vaccine uptake, and vaccine efficacy data from the 10 non-pandemic seasons from 2003/2004 to 2013/2014 were used, and cost data were drawn mainly from a health insurance claims data analysis and supplemented by estimates from literature. Uncertainty is explored via scenario, deterministic, and probabilistic sensitivity analyses.

RESULTS

Vaccinating 2- to 9-year-olds with QIV assuming a vaccine uptake of 40% is cost-saving with a benefit-cost ratio of 1.66 from a societal perspective and an incremental cost-effectiveness ratio of €998/QALY from a TPP perspective. Lower and higher vaccine uptakes show marginal effects, while extending the target group to 2- to 17-year-olds further increases the health benefits while still being below the willingness-to-pay (WTP) threshold. Assuming no vaccine-induced herd protection has a negative effect on the cost-effectiveness ratio, but childhood vaccination remains cost-effective.

CONCLUSION

Routine childhood vaccination against seasonal influenza in Germany is most likely to be cost-saving from a societal perspective and highly cost-effective from a TPP perspective.

Authors+Show Affiliations

Immunization Unit, Robert Koch-Institute, Berlin, Germany; School of Public Health, Bielefeld University, Bielefeld, Germany. Electronic address: scholzs@rki.de.Immunization Unit, Robert Koch-Institute, Berlin, Germany.School of Public Health, Bielefeld University, Bielefeld, Germany.Immunization Unit, Robert Koch-Institute, Berlin, Germany.School of Public Health, Bielefeld University, Bielefeld, Germany.Immunization Unit, Robert Koch-Institute, Berlin, Germany.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33431151

Citation

Scholz, Stefan M., et al. "Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany." Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research, vol. 24, no. 1, 2021, pp. 32-40.
Scholz SM, Weidemann F, Damm O, et al. Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany. Value Health. 2021;24(1):32-40.
Scholz, S. M., Weidemann, F., Damm, O., Ultsch, B., Greiner, W., & Wichmann, O. (2021). Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany. Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research, 24(1), 32-40. https://doi.org/10.1016/j.jval.2020.05.022
Scholz SM, et al. Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany. Value Health. 2021;24(1):32-40. PubMed PMID: 33431151.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany. AU - Scholz,Stefan M, AU - Weidemann,Felix, AU - Damm,Oliver, AU - Ultsch,Bernhard, AU - Greiner,Wolfgang, AU - Wichmann,Ole, Y1 - 2020/11/05/ PY - 2019/08/26/received PY - 2020/04/23/revised PY - 2020/05/25/accepted PY - 2021/1/12/entrez PY - 2021/1/13/pubmed PY - 2021/1/13/medline KW - children KW - cost-effectiveness KW - decision analytic model KW - health economics KW - influenza KW - vaccine SP - 32 EP - 40 JF - Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research JO - Value Health VL - 24 IS - 1 N2 - OBJECTIVES: In Germany, routine influenza vaccination with quadrivalent influenza vaccines (QIV) is recommended and reimbursed for individuals ≥60 years of age and individuals with underlying chronic conditions. The present study examines the cost-effectiveness of a possible extension of the recommendation to include strategies of childhood vaccination against seasonal influenza using QIV. METHODS: A dynamic transmission model was used to examine the epidemiological impact of different childhood vaccination strategies. The outputs were used in a health economic decision tree to calculate the costs per quality-adjusted life year (QALY) gained from a societal and a third-party payer (TPP) perspective. Strain-specific epidemiology, vaccine uptake, and vaccine efficacy data from the 10 non-pandemic seasons from 2003/2004 to 2013/2014 were used, and cost data were drawn mainly from a health insurance claims data analysis and supplemented by estimates from literature. Uncertainty is explored via scenario, deterministic, and probabilistic sensitivity analyses. RESULTS: Vaccinating 2- to 9-year-olds with QIV assuming a vaccine uptake of 40% is cost-saving with a benefit-cost ratio of 1.66 from a societal perspective and an incremental cost-effectiveness ratio of €998/QALY from a TPP perspective. Lower and higher vaccine uptakes show marginal effects, while extending the target group to 2- to 17-year-olds further increases the health benefits while still being below the willingness-to-pay (WTP) threshold. Assuming no vaccine-induced herd protection has a negative effect on the cost-effectiveness ratio, but childhood vaccination remains cost-effective. CONCLUSION: Routine childhood vaccination against seasonal influenza in Germany is most likely to be cost-saving from a societal perspective and highly cost-effective from a TPP perspective. SN - 1524-4733 UR - https://www.unboundmedicine.com/medline/citation/33431151/Cost_Effectiveness_of_Routine_Childhood_Vaccination_Against_Seasonal_Influenza_in_Germany_ DB - PRIME DP - Unbound Medicine ER -